Study: Effective vaccine response among young By WANG XIAOYU | China Daily | Updated: 2021-07-03 07:50 A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing, March 16, 2020. [Photo/Xinhua]
The domestic COVID-19 vaccine developed by Sinovac Biotech is safe and can elicit a strong antibody response in people aged 3 to 17 in early and mid-stage clinical trials, according to a study published recently in a medical journal.
The study is the world s first that examines the safety and protection effects of a COVID-19 vaccine for children as young as 3 years old. It also came as the spread of highly transmissible variants worldwide has prompted calls for accelerating mass immunization, and more countries are considering expanding the use of vaccines to cover young people, including China.
Effective vaccine response among young
1 2021-07-03 09:45:03China Daily
Editor : Zhang Dongfang
ECNS App Download A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing, March 16, 2020. [Photo/Xinhua]
The domestic COVID-19 vaccine developed by Sinovac Biotech is safe and can elicit a strong antibody response in people aged 3 to 17 in early and mid-stage clinical trials, according to a study published recently in a medical journal.
The study is the world s first that examines the safety and protection effects of a COVID-19 vaccine for children as young as 3 years old. It also came as the spread of highly transmissible variants worldwide has prompted calls for accelerating mass immunization, and more countries are considering expanding the use of vaccines to cover young people, including China.
China's formal crackdown and U-turn on the use of the cannabis-derived ingredient cannabidiol (CBD) in cosmetics production, while not surprising, represents a significant blow to the fledgling market that had quadrupled in the past year. Drug regulator, the National Medical Products Administration (NMPA), last week banned the use of CBD - a compound found in the cannabis plant - in.
See eTable 1 in Supplement 2 for definitions of each analysis population. Among those receiving aluminum hydroxide (alum) for the first dose, 5 participants received WIV04 (n = 2) and HB02 (n = 3) vaccines for the second dose and were not included in the safety analysis population of the alum-only group (13 458 – 5 = 13 453), but were included in the WIV04 and HB02 groups, respectively. Three participants who received WIV04 for the first dose and HB02 for the second dose and 3 participants who received HB02 for the first dose and WIV04 for the second dose were included in both groups (WIV04: 13 459 + 2 + 3 = 13 464; HB02: 13 465 + 3 + 3 = 13 471). To measure neutralization antibody levels, the first 900 participants from each study site were selected. There were 9 participants in the WIV04 group, 7 in the HB02 group, and 8 in alum-only group who had adverse events or serious adverse events (SAEs) after the first dose and did not receive the secon
China CBD ban: Asia Horizon CEO suggests how China can better regulate CBD cosmetics market China-based CBD company Asia Horizon has suggested a few ‘straightforward’ ways China can go about regulating CBD cosmetics instead of implementing a blanket ban over the category.
On March 26, the National Institutes for Food and Drug Control (NIFDC), announced a proposal to introduce legislation that would prohibit the use of cannabis and cannabis extracts in cosmetics.
The ban would include raw materials such as cannabidiol (CBD), Cannabis sativa kernel fruit, cannabis sativa seed oil, as well as cannabis sativa leaf.
Asia Horizon is Chinese hemp company that distributes Westerns CBD brands in Asia ranging from cosmetics to health supplements. Last year, the firm partnered with German CBD beauty brand Nordic Cosmetics to enter China via online flagship store on Chinese e-commerce platform Tmall – its first venture bringing in a Western CBD brand into